DAGLB
ENSG00000164535
Target class
Enzyme
Chromosome
7
- Chemical probe available
- Yes
- Target name
- DAGLB
- Gene name
- Diacylglycerol lipase beta
- Gene symbol
- DAGLB
- Protein name
- Diacylglycerol lipase-beta (DAGL-beta) (DGL-beta) (EC 3.1.1.116) (KCCR13L) (PUFA-specific triacylglycerol lipase) (EC 3.1.1.3) (Sn1-specific diacylglycerol lipase beta)
- KCCR13L
- DAGLBETA
- Gene biotype
- Protein coding
- Gene family
- Lipases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 28.78
- Tissue specificity (Gini)
- 0.218
- Tissue specificity (tau)
- 0.485
- KEGG gene identifiers
- hsa:221955
- Reactome pathways
- R-HSA-426048
- Protein interaction confidence
- 0.820714
- Protein interaction partners
- 7
- End position
- 6484190
- Start position
- 6407846
- Chromosome
- 7
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Nucleoplasm
- Plasma membrane
Publication evidence
- PubMed 14610053
- Tissue specificity (tau)
- 0.4854
- Expression inequality (Gini)
- 0.217936
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 28.78
- Lung
- 27.17
- Adrenal Gland
- 26.72
- Skin - Not Sun Exposed (Suprapubic)
- 25.27
- Brain - Cerebellar Hemisphere
- 24.12
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)28.78
- Lung27.17
- Adrenal Gland26.72
- Skin - Not Sun Exposed (Suprapubic)25.27
- Brain - Cerebellar Hemisphere24.12
- Spleen23.61
- Brain - Cerebellum23.3
- Thyroid21.83
- Brain - Frontal Cortex (BA9)20.77
- Nerve - Tibial20.53
- Ovary20.39
- Cells - Cultured fibroblasts20.29
- Brain - Cortex20
- Vagina18.55
- Uterus18.16
- Cervix - Endocervix17.93
- Testis17.64
- Fallopian Tube17.13
- Cervix - Ectocervix16.92
- Adipose - Subcutaneous16.72
- Prostate16.56
- Whole Blood15.96
- Breast - Mammary Tissue15.77
- Small Intestine - Terminal Ileum15.56
- Esophagus - Mucosa15.18
And 29 more, listed on the interactive page.
Biological processes
- GO:0019369
- GO:0005765
- GO:0005886
- GO:0005515
- GO:0016298
- GO:0047372
Related records
Trials (58)
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Comparison of MAG and Fish Oil Efficacy
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Effect of Orlistat in Body Composition
- Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial
- Effectiveness of Brief Counseling for Weight Management
- Efficacy and Safety of ATL-962 in Obese Diabetics
- Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease